| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/26/2011 | CA2446112C A method for regulating immune function in primates using the foxp3 protein |
| 04/26/2011 | CA2441260C Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability |
| 04/26/2011 | CA2423628C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 04/26/2011 | CA2420231C Antibodies to human il-1.beta. |
| 04/26/2011 | CA2359945C Inhibitors of crystallization in a solid dispersion |
| 04/26/2011 | CA2345103C (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| 04/26/2011 | CA2337971C Novel anti-diabetic peptides |
| 04/26/2011 | CA2319093C Sea cucumber carotenoid lipid fraction products and methods of use |
| 04/26/2011 | CA2264012C Compositions and methods for polynucleotide delivery |
| 04/21/2011 | WO2011047262A2 Dual variable domain immunoglobulins and uses thereof |
| 04/21/2011 | WO2011046851A1 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes |
| 04/21/2011 | WO2011046101A1 Fat accumulation suppressor |
| 04/21/2011 | WO2011045732A2 A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity |
| 04/21/2011 | WO2011045292A1 Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
| 04/21/2011 | WO2011045081A1 Use of lactoferrin and lactoferrin-containing compositions |
| 04/21/2011 | WO2011044751A1 Foliamangiferosides, preparation method and use thereof |
| 04/21/2011 | WO2011011919A8 Composition for lowering blood glucose |
| 04/21/2011 | WO2011008054A3 Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same |
| 04/21/2011 | WO2010141810A3 Compositions and methods modulating mg29 for the treatment of diabetes |
| 04/21/2011 | WO2010138802A3 Compositions and their use for removing cholesterol |
| 04/21/2011 | WO2010135684A9 Bone morphogenetic proteins for the treatment of insulin resistance |
| 04/21/2011 | WO2010132502A3 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| 04/21/2011 | WO2008080988A3 Cyclopentanone derivatives, method of synthesis and uses thereof |
| 04/21/2011 | US20110092669 Synthesis of cyclosporin analogs |
| 04/21/2011 | US20110092599 Use of Treprostinil to treat neuropathic diabetic foot ulcers |
| 04/21/2011 | US20110092594 Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| 04/21/2011 | US20110092577 Inositol Pyrophosphates Determine Exocytotic Capacity |
| 04/21/2011 | US20110092572 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 04/21/2011 | US20110092563 Statin and omega-3 fatty acids for lipid therapy |
| 04/21/2011 | US20110092555 Thiazolidinedione compound |
| 04/21/2011 | US20110092553 Substituted Azole Derivatives, Compositions, and Methods of Use |
| 04/21/2011 | US20110092552 Treatment and Prevention of Major Adverse Cardiovascular Events or Major Coronary Events by Administering Omega-3 Fatty Acids |
| 04/21/2011 | US20110092547 Chemical compounds 979 |
| 04/21/2011 | US20110092545 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding |
| 04/21/2011 | US20110092540 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 04/21/2011 | US20110092531 Novel Spiropiperidine Compounds |
| 04/21/2011 | US20110092526 Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 |
| 04/21/2011 | US20110092517 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases |
| 04/21/2011 | US20110092516 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases |
| 04/21/2011 | US20110092512 New hsl inhibitors useful in the treatment of diabetes |
| 04/21/2011 | US20110092510 Dpp-iv inhibitors for use in the treatment of nafld |
| 04/21/2011 | US20110092506 Trisubstituted amine compound |
| 04/21/2011 | US20110092501 Novel inhibitors |
| 04/21/2011 | US20110092499 N-containing heterocyclic compounds |
| 04/21/2011 | US20110092492 Imidazo compounds |
| 04/21/2011 | US20110092490 Pyrimidines, triazines and their use as pharmaceutical agents |
| 04/21/2011 | US20110092487 Novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza-bicyclo[3.3.1]-nonane-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/21/2011 | US20110092474 Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor |
| 04/21/2011 | US20110092468 Pharmaceutical Calcimimetics |
| 04/21/2011 | US20110092448 Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics |
| 04/21/2011 | US20110092447 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions |
| 04/21/2011 | US20110092419 Protease-stabilized insulin analogues |
| 04/21/2011 | US20110092417 Leptin fusion proteins |
| 04/21/2011 | US20110092416 Vitamine B12 - Peptide Conjugates for Oral Delivery |
| 04/21/2011 | US20110091876 Zcytor19 polynucleotides, polypeptides, antibodies and methods of use |
| 04/21/2011 | US20110091572 Acne treatment compositions comprising nanosilver and uses |
| 04/21/2011 | US20110091543 Oral delivery of modified transferrin fusion proteins |
| 04/21/2011 | US20110091538 Polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof |
| 04/21/2011 | US20110091508 Oligofluorinated cross-linked polymers and uses thereof |
| 04/21/2011 | US20110091474 Compositions and Methods For Diagnosing and Treating Diabetic Micro Vascular Complications |
| 04/21/2011 | US20110091472 Compositions for treating psoriasis |
| 04/21/2011 | US20110091469 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 04/21/2011 | US20110091468 Connective tissue growth factor antibodies |
| 04/21/2011 | US20110091467 Compositions and methods for modulating dopamine neurotransmission |
| 04/21/2011 | US20110091463 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | US20110091461 Binding domain-immunoglobulin fusion proteins |
| 04/21/2011 | US20110091447 Lymphocyte control of obesity and insulin resistance |
| 04/21/2011 | US20110091440 Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases |
| 04/21/2011 | US20110091434 Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase |
| 04/21/2011 | US20110091407 Polymer derived from linear polyethylenimine for gene transfer |
| 04/21/2011 | DE102009049702A1 Verwendung von Lactoferrin und Lactoferrin enthaltende Zusammensetzungen Use of lactoferrin and lactoferrin containing compositions |
| 04/21/2011 | CA2777775A1 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes |
| 04/21/2011 | CA2777717A1 Chimeric fibroblast growth factors with altered receptor specificity |
| 04/21/2011 | CA2777240A1 Enteral administration of arginine-glutamine dipeptide to support retinal, intestinal, or nervous system development |
| 04/21/2011 | CA2776457A1 Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
| 04/21/2011 | CA2775959A1 Dual variable domain immunoglobulins and uses thereof |
| 04/21/2011 | CA2773975A1 Fat accumulation suppressor |
| 04/21/2011 | CA2735343A1 Compositions that include anthocyanidins and methods of use |
| 04/20/2011 | EP2311955A2 Osteoprotegerin binding proteins and their receptors |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |
| 04/20/2011 | EP2311847A1 Composition containing stable vitamin B6 derivative |
| 04/20/2011 | EP2311834A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 04/20/2011 | EP2311822A1 Gpr119 agonist |
| 04/20/2011 | EP2311818A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| 04/20/2011 | EP2311811A1 Novel spiro compound, and pharmaceutical preparation comprising the same |
| 04/20/2011 | EP2311494A1 Histone modification inhibitor specific to target gene |
| 04/20/2011 | EP2311484A1 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases |
| 04/20/2011 | EP2311451A1 Amino-methyl substituted tetracycline compounds |
| 04/20/2011 | EP2311447A1 Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof |
| 04/20/2011 | EP2311440A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 04/20/2011 | EP2310504A1 Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
| 04/20/2011 | EP2310374A1 Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists |
| 04/20/2011 | EP2310372A2 Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| 04/20/2011 | EP2310371A2 Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia |
| 04/20/2011 | EP2310368A1 Small molecule leptin receptor modulators |
| 04/20/2011 | EP2310366A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 04/20/2011 | EP2310042A1 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia |
| 04/20/2011 | EP2310037A2 Conglutin-gamma as medicament and diet supplement |
| 04/20/2011 | EP2310003A1 Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue |